Argenx Se · EURONEXT:ARGX
Argenx — Q3 2026 Earnings Presentation
14 slides from Argenx's earnings presentation, Oct 22, 2026
Slide 1: Leading a new era of innovation in immunology
Leading a new era of innovation in immunology 3Q 2026 Financial Results Call | October 22,2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Connecting science and patients to unlock infinite opportunity
Connecting science and patients to unlock infinite opportunity Science Patients 3
Slide 4: Moving Towards Reaching 50,000 Patients in 2030
Moving Towards Reaching 50,000 Patients in 2030 Efgartigimod Empasiprubart 5Up to 5 Pediatric gMG PDUFA date February 2027 IMNM sBLA on track for submission by YE Mike, potential MMN Patient launches in 2027 Ocular MG Autoinjector Multifocal motor neuropathy (MMN) sBLA submitted Potential launch in
Slide 5: Empasiprubart: Entrepreneurial Science in Action
Empasiprubart: Entrepreneurial Science in Action Conviction in EMPASSION MMN at a glance 12k patients across key markets Biologic rationale supports C2 as the right target UNMET NEED 40% Initially 0 Targeted 60% Progression misdiagnosed treatments despite treatment Strength of Phase 2 ARDA and ARDA+
Slide 6: FB102: Phase 3-Ready with Pipeline-in-a-Product Potential
FB102: Phase 3-Ready with Pipeline-in-a-Product Potential Positive Phase 2 data in celiac disease First Phase 2 evidence that CD122 can prevent FB102 gluten-induced intestinal damage Moving to Phase 3 Applying the argenx playbook to FB102 Expand into alopecia areata, vitiligo and other autoimmune di
Slide 7: Product Net Sales of $1.7 Billion in Q3
Product Net Sales of $1.7 Billion in Q3 Quarter over Quarter (QoQ) growth: 3Q26 vs 2Q26 $’m Product Net Sales by Quarter 1,721 (in millions of $) Q3 2026 Q2 2026 Growth QoQ Growth % * China 1,516 US 1,471 1,273 198 16% RoW Japan 1) 81 102 (21) (20)% Japan 1,286 1,298 Rest of the World 158 136 22 17%
Slide 8: Q3 2026 Financial Summary
Q3 2026 Financial Summary Three months ended Nine months ended Operating margin of 28%; September 30 September 30 Adjusted operating profit (in million of $) 2026 2025 2026 2025 margin† of 37% excluding $150 million in acquisition- Product net sales $ 1,721 1,127 4,534 2,866 Other operating income 3
Slide 9: Patient-first Commercial Execution
Patient-first Commercial Execution Consistent CIDP Strong quarterly patient Seronegative driving patient and prescriber growth in MG and CIDP halo effect across MG adds VYVGART Patient 9
Slide 10: VYVGART Has the Broadest gMG Label
VYVGART Has the Broadest gMG Label Seronegative Launch Next Growth Drivers Halo Effect Potential MG 2027 launches Label expansion lifting growth across all of gMG Breadth Ocular MG Pediatric MG Autoinjector >10% of seronegative prescribers new to VYVGART Access Moving earlier in treatment paradigm ~
Slide 11: CIDP: Steady Growth Built on Evidence and Experience
CIDP: Steady Growth Built on Evidence and Experience EVIDENCE GENERATION1 5+ yrs Most extensive dataset in CIDP ~40% Stage A responders reached INCAT 0–1 PHOTO: GAYLE Image to come from Cristian 87.5% Treatment-naïve patients improved 87% Of patients successfully transitioned from IVIg to VYVGART 1-
Slide 12: IMNM: First Potential Step Into Rheumatology
IMNM: First Potential Step Into Rheumatology HIGH UNMET NEED No approved therapies 20,000 patients in the US Melissa, FDA Breakthrough Therapy Myositis Patient Designation For people living with myositis, the goal is straightforward: regain strength 9/10 Rheumatologists likely to and function, and g
Slide 13: We are on a bold mission
We are on a bold mission Transforming the lives of patients with severe autoimmune disease through immunology innovation 13
Slide 14: Alternative Performance Measure Statement
Alternative Performance Measure Statement In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using the following non-IFRS financial measures, or Alternative Performance Measures (APMs): (i) cash, cash equivalents and current financial a